Pfizer India shares witnessed a significant rally today, climbing over 9% to reach 5,209 INR following the announcement of robust financial results for the third quarter of fiscal year 2026. This surge is backed by a 20% year-on-year increase in operational revenue, which reached 645 crore INR, and an 11% rise in net profit to 141.8 crore INR. The company’s profitability was notably influenced by exceptional items totaling 58.20 crore INR. A primary component of these costs involves a strategic shift in the domestic business model. Pfizer has entered into a landmark 5-year exclusive agreement with Cipla for the marketing and distribution of key legacy brands, including Corex, Dolonex, and Neksium. This partnership aims to leverage Cipla’s extensive distribution network while allowing Pfizer to transition toward an asset-light commercial model. As part of this transition, the company recorded a one-time charge of 39.58 crore INR related to personnel separation costs for its field and marketing staff. Further financial impact was noted due to the nationwide implementation of new labor laws. Following the consolidation of regulations into four New Labour Codes, Pfizer revised its employee benefit provisions upward by 18.62 crore INR. This adjustment primarily stems from new wage definitions that affect gratuity and other social security liabilities. From a market perspective, Pfizer's market capitalization now stands at approximately 23,833 crore INR. The stock has delivered a 21% return over the past year, reflecting resilient investor confidence. Technical indicators show a strong bullish momentum, with the stock trading above all major simple moving averages. Institutional activity remains steady, as Foreign Portfolio Investors marginally increased their positions during the December quarter. While domestic mutual funds saw a slight reduction in holdings to 11.71%, analysts maintain a positive outlook on the stock's valuation, which currently trades at a Price-to-Earnings ratio of approximately 25.5. The broader pharmaceutical sector continues to show strength as multinational companies optimize their portfolios. By outsourcing high-cost promotional activities to local partners like Cipla, Pfizer is positioning itself to focus on high-value innovations and vaccines while maintaining the steady revenue streams of its established brands.